(USA Today) Johnson & Johnson submitted paperwork Thursday requesting that the U.S. Food and Drug Administration authorize its COVID-19 vaccine for use in adults.
The FDA announced later in the evening that its advisory committee will meet Feb. 26 to discuss the application. The agency is expected to authorize the vaccine within a few days of that meeting, making it the third available to the American public.
J&J announced last week that its vaccine was 72% effective in a U.S. trial, though it was less effective among people in Latin America and South Africa, bringing overall effectiveness down to 66%.